Effect of Nebulized Dexmedetomidine on Central Sensitization and Chronification in Migraine
Recruiting · NCT07769255 · Interventional (participants receive a specific treatment) · Lead sponsor: Beni-Suef University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Migraine is a debilitating neurological disorder characterized by recurrent headaches episodes, often accompanied by amplified perception of multiple sensory inputs such as cutaneous allodynia, photophobia, and phonophobia. The suggested mechanism in migraine is likely through sensitized trigeminovascular and dysfunctional pain modulatory systems. Dexmedetomidine, a selective α2-adrenergic receptor agonist, exerts central antinociceptive effects by reducing neuronal hyperexcitability, glial activation, and CGRP expression. Nebulized administration provides a non-invasive alternative to intravenous use, with rapid CNS absorption and minimal sedation .
Who can take part
Inclusion criteria
- Diagnosis of Early chronic migraine (\<6 months of ≥15 headache days/month), per ICHD-3 criteria.
- No preventive migraine therapy in the prior 8 weeks.
Exclusion criteria
- Presence of cardiopulmonary, psychiatric, or neurological comorbidities.
- Current use of sedatives, opioids, or CGRP-targeting therapies.
- Pregnancy or breastfeeding.
Where it is running
1 location listed.
- Beni-Suef University Hospital - Banī Suwayf, Egypt